Comparative effectiveness research: From clinical information to economic incentives

Health Affairs

Volumn 29, Issue 10, 2010, Pages 1788-1795

  Robinson, James C ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; COMPARATIVE EFFECTIVENESS; COST CONTROL; MEDICAL INFORMATICS; REIMBURSEMENT; UNITED STATES;

COMPARATIVE EFFECTIVENESS RESEARCH; COST CONTROL; MEDICAL INFORMATICS; REIMBURSEMENT, INCENTIVE; UNITED STATES;

EID: 79952116512     PISSN: 02782715     EISSN: 15445208     Source Type: Journal    
DOI: 10.1377/hlthaff.2010.0605     Document Type: Article

References (43)

1. Antos J, Bertko J, Chernew M, Cutler D, Goldman D, McClellan MB, et al. Bending the curve: effective steps to address long-term health care spending growth [Internet]. Washington (DC): Brookings Institution; 2009 Aug [cited 2010 Sep 3]. Available from: http://www.brookings.edu/~/media/Files/rc/reports/2009/0826_btc/0826_btc_fullreport.pdf
2. Congressional Budget Office. Research on the comparative effectiveness of medical treatments: issues and options for an expanded federal role [Internet]. Washington (DC): CBO; 2007 Dec [cited 2010 Sep 3]. Available from: http://www.cbo.gov/ftpdocs/88xx/doc8891/Frontmatter.1.2.shtml
3. Winstein KJ. A simple health-care fix fizzles out. Wall Street Journal. 2010 Feb 11.
4. Robinson JC. Insurers' strategies for managing the use and cost of biopharmaceuticals. Health Aff (Millwood). 2006;25(5):1205-17.
5. Hoffman A, Pearson SD. "Marginal medicine": targeting comparative effectiveness research to reduce waste. Health Aff (Millwood). 2009;28(4):w710-8.
6. Radley DC, Finkelstein SN, Stafford RS. Off-label prescribing among office- based physicians. Arch Intern Med. 2006;166:1021-6.
7. Hochman M, McCormick D. Characteristics of published comparative effectiveness studies of medications. JAMA. 2010;303(10):951-8.
8. Garber AM. Evidence-based coverage policy. Health Aff (Millwood). 2001;20(5):62-82.
9. Morrow DJ. Some HMOs plan limited coverage for new arthritis drug. New York Times. 1999 Jan 8.
10. Mohr PE, Tunis SR. Access with evidence development: the US experience. Pharmacoeeconomics. 2010;28(2):153-62.
11. Tunis SR, Pearson SD. Coverage options for promising technologies: Medicare's "coverage with evidence development." Health Aff (Millwood). 2006;25(5):1218-30.
12. Freudenheim M. Big HMO to give decisions on care back to doctors. New York Times. 1999 Nov 9.
13. Appleby J. The case of CT angiography: how Americans view and embrace new technology. Health Aff (Millwood). 2008;27(6):1515-21.
14. Blumenauer E. My near death panel experience. New York Times. 2009 Nov 14.
15. Robinson JC. The end of managed care. JAMA. 2001;285(20):2622-8.
16. Robinson JC. Renewed emphasis on consumer cost sharing in health insurance benefit design. Health Aff (Millwood). 2002;21:w139-54.
17. Herzlinger RE, editor. Consumerdriven health care: implications for providers, payers, and policymakers. San Francisco (CA): Jossey-Bass; 2004.
18. Lee TH, Emanuel EJ. Tier 4 drugs and the fraying of the social compact. N Engl J Med. 2008;359(4): 333-5.
19. Chernew ME, Juster IA, Shah M, Wegh A, Rosenberg S, Rosen AB, et al. Evidence that value-based insurance can be effective. Health Aff (Millwood). 2010;29(3):530-6.
20. Neumann PJ, Auerbach HR, Cohen JT, Greenberg D. Low-value services in value-based insurance design. Am J Manag Care. 2010;16(4):280-6.
21. Goldman DP, Joyce GF, Zheng Y. Prescription drug cost sharing: associations with medication and medical utilization and spending and health. JAMA. 2007;298(1): 61-9.
22. Danzon PM, Pauly MV. Health insurance and the growth in pharmaceutical expenditures. J Law Econ. 2002;45:587-613.
23. US Government Accountability Office. Medicare Part D: spending, beneficiary cost sharing, and costcontainment efforts for high-cost drugs eligible for a specialty tier [Internet]. Washington (DC): GAO; 2010 Jan 29 [cited 2010 Sep 7]. Available from: http://www.gao.gov/products/GAO-10-242
24. Robinson JC. Application of valuebased insurance design principles to high-cost health services. Health Aff (Millwood). Forthcoming.
25. Zelman WA, Berenson RA. The managed care blues and how to cure them. Washington (DC): Georgetown University Press; 1998.
26. Robinson JC, Casalino LP. Reevaluation of capitation contracting in New York and California. Health Aff (Millwood). 2001;20:w11-9.
27. Abelson R. Insurers push plans that limit choice of doctor. New York Times. 2010 Jul 17.
28. Fisher ES, Wennberg DE, Stukel TA, Gottlieb DJ, Lucas FL, Pinder EL. The implications of regional variations in Medicare spending. Part 1: the content, quality, and accessibility of care. Ann Intern Med. 2003;138 (4):273-87.
29. Claxton G, Gabel JR, DiJulio B, Pickreign J, Whitmore H, Finder B, et al. Health benefits in 2008: premiums moderately higher, while enrollment in consumer-directed plans rises in small firms. Health Aff (Millwood). 2008;27(6):w492-502.
30. Robinson JC. Hospital tiers in health insurance: balancing consumer choice with financial incentives. Health Aff (Millwood). 2003;22: w135-46.
31. Iglehart JK. Health insurers and medical-imaging policy-a work in progress. N Engl J Med. 2009;360: 1030-7.
32. Centers for Medicare and Medicaid Services. Decision memo for carotid artery stenting [Internet]. Baltimore (MD): CMS; [cited 2010 Sep 7]. Available from: http://www.cms.hhs.gov/mcd/viewdecisionmemo.asp?from2=viewdecisionmemo.asp&id=157&
33. Robinson JC, Williams T, Yanagihara D. Measurement of and reward for efficiency in California's pay-forperformance program. Health Aff (Millwood). 2009;28(5):1438-47.
34. Steinbrook R. The end of fee-forservice medicine? Proposals for payment reform in Massachusetts. N Engl J Med. 2009;361(11):1036-8.
35. Hackbarth G, Reischauer R, Mutti A. Collective accountability for medical care-toward bundled Medicare payments. N Engl J Med. 2008; 369(1):3-5.
36. De Brantes F, Rosenthal MB, Painter M. Building a bridge from fragmentation to accountability-the Prometheus payment model. N Engl J Med. 2009;361(11):1033-6.
37. Phillips KA, Vennstra DL, Ramsey SD, Van Bebber SL, Sakowski J. Genetic testing and pharmacogenomics: issues for determining the impact to healthcare delivery and costs. Am J Manag Care. 2004;10: 425-32.
38. Garber AM, McClellan MB. Satisfaction guaranteed-"payment by results" for biologic agents. N Engl J Med. 2007;357(16):1575-7.
39. Gregson N, Sparrowhawk K, Masukopf J, Paul J. Pricing medicines: theory and practice, challenges and opportunities. Nat Rev Drug Discov. 2005;4:121-30.
40. Carlson JJ, Sullivan SD, Garrison LP, Neumann PJ, Veenstra DL. Linking payment to health outcomes: a taxonomy and examination of performance- based reimbursement schemes between healthcare payers and manufacturers. Health Policy. 2010;96(3):179-90.
41. Pollack A. Drug deals tie prices to how well patients do. New York Times. 2009 Apr 22.
42. Carman KL, Maurer M, Yegian JM, Dardess P, McGee J, Evers M, et al. Evidence that consumers are skeptical about evidence-based health care. Health Aff (Millwood). 2010; 29(7):1400-6.
43. Institute of Medicine. Learning what works best: the nation's need for evidence on comparative effectiveness in health care. Washington (DC): National Academies Press; 2007.